The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death

被引:54
作者
Chari, Nikhil S. [1 ]
Pinaire, Nicole L. [1 ]
Thorpe, Lynnelle [1 ]
Medeiros, L. Jeffrey [1 ]
Routbort, Mark J. [1 ]
McDonnell, Timothy J. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
关键词
Apoptosis; p53; Therapy; Cancer; MicroRNA; Tumor suppressors; SMALL-MOLECULE INHIBITORS; MDM2 GENE AMPLIFICATION; DOWN-REGULATION; BCL-2; FAMILY; DNA-DAMAGE; STEM-CELLS; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; T-ANTIGEN; EXPRESSION;
D O I
10.1007/s10495-009-0327-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The molecular subversion of cell death is acknowledged as a principal contributor to the development and progression of cancer. The p53 tumor suppressor protein is among the most commonly altered proteins in human cancer. The p53 protein mediates critical functions within cells including the response to genotoxic stress, differentiation, senescence, and cell death. Loss of p53 function can result in enhanced rates of cell proliferation, resistance to cell death stimuli, genomic instability, and metastasis. The community of cancer scientists is now in possession of a vast repository of information regarding the frequency, specific mechanisms, and clinical context of cell death deregulation in cancer. This information has enabled the design of therapeutic agents to target proteins, including p53. The feasibility and impact of targeting cell death signaling proteins has been established in preclinical models of human cancer. The appropriate application of these targeted agents is now being established in clinical trials.
引用
收藏
页码:336 / 347
页数:12
相关论文
共 174 条
  • [101] P53 suppresses the self-renewal of adult neural stem cells
    Meletis, K
    Wirta, V
    Hede, SM
    Nistér, M
    Lundeberg, J
    Frisén, J
    [J]. DEVELOPMENT, 2006, 133 (02): : 363 - 369
  • [102] Michael MZ, 2003, MOL CANCER RES, V1, P882
  • [103] p63 is a p53 homologue required for limb and epidermal morphogenesis
    Mills, AA
    Zheng, BH
    Wang, XJ
    Vogel, H
    Roop, DR
    Bradley, A
    [J]. NATURE, 1999, 398 (6729) : 708 - 713
  • [104] EXPRESSION OF BCL-X(L) CAN CONFER A MULTIDRUG-RESISTANCE PHENOTYPE
    MINN, AJ
    RUDIN, CM
    BOISE, LH
    THOMPSON, CB
    [J]. BLOOD, 1995, 86 (05) : 1903 - 1910
  • [105] Miyake H, 1999, CANCER RES, V59, P4030
  • [106] MIYASHITA T, 1995, CELL, V80, P293
  • [107] The MDM2 gene amplification database
    Momand, J
    Jung, D
    Wilczynski, S
    Niland, J
    [J]. NUCLEIC ACIDS RESEARCH, 1998, 26 (15) : 3453 - 3459
  • [108] mir-29 regulates Mcl-1 protein expression and apoptosis
    Mott, J. L.
    Kobayashi, S.
    Bronk, S. F.
    Gores, G. J.
    [J]. ONCOGENE, 2007, 26 (42) : 6133 - 6140
  • [109] Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a
    Murphy, M
    Ahn, J
    Walker, KK
    Hoffman, WH
    Evans, RM
    Levine, AJ
    George, DL
    [J]. GENES & DEVELOPMENT, 1999, 13 (19) : 2490 - 2501
  • [110] Targeting protein-protein interactions: Lessons from p53/MDM2
    Murray, Justin K.
    Gellman, Samuel H.
    [J]. BIOPOLYMERS, 2007, 88 (05) : 657 - 686